Evaluation of the Minimally Invasive VenTouch™ System in the Treatment of Functional Mitral Valve Regurgitation (FMR)

NAUnknownINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

July 4, 2017

Study Completion Date

December 31, 2020

Conditions
Functional Mitral Regurgitation
Interventions
DEVICE

VenTouch System Implant

The VenTouch System is intended for use in the treatment of functional MR (FMR) in adults who are symptomatic despite optimal medical management. It is intended for subjects with FMR with essentially normal leaflet anatomy and motion, with mitral valve regurgitation attributable mainly to annular dilatation with or without papillary muscle displacement. It is not intended to treat structural defects/degeneration of the mitral valve. The VenTouch System is used to reshape the base of the heart to bring the mitral valve leaflets into better coaptation. By doing so, it brings the mitral valve leaflets closer, allowing proper closure of the valve, and reducing or eliminating MR. There is provision of support to the ventricular myocardium below the annulus as well as the annulus, so the VenTouch System may allow long-term ventricular remodeling with positive impact on the functionality of the mitral valve.

Trial Locations (2)

15030

Na Homolce Hospital, Prague

33604

Bordeaux Heart University Hospital, Bordeaux

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Mardil Medical

INDUSTRY